Recently, the FDA published warnings regarding adverse events with the use of inferior vena cava filters for the prevention of pulmonary embolus. The CTAF examines the evidence.

The end point of the study was the recurrence of symptomatic venous thromboembolism, confirmed by venography or ventilation–perfusion lung scanning according to the above-listed diagnostic criteria.

Inferior vena cava filters have been compared to no filters in only two studies, one of which only included patients with hip fractures and the other high risk patients.

Check out our CAVA stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Find out if Cava Group Inc (CAVA:XNYS) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value of the company's share ...

On July 2, 2025, IVC will host IVC Summit 2025 in Kyoto, Japan — a curated industry forum bringing together Japan’s leading ecosystem players and cutting-edge Web3 innovators.

Dalton, Georgia – IVC U.S., Inc. adds J.H. Freed & Sons, Floor Supply Distributors and New England Floor Supply to their current list of active distributors thus increasing coverage of their ...

In the RIETE registry (Computerized Registry of Patients With Venous Thromboembolism) of >40 000 patients with VTE, a subset of 344 cases with IVC filter insertion attributable to high risk of ...